L'Oreal boosted by pick-up in Chinese demand
Top French luxury goods companies L'Oreal and Kering reported strong third quarter sales due to a rebound in demand in key Chinese markets, which helped offset the devastating impact of the coronavirus pandemic.
Cosmetics giant L'Oreal said sales were down by 2.0 percent at 7.04 billion euros in the three months to September.
For the nine months to September, sales were up 8.6 percent from the same period last year at 20.11 billion euros as the company benefited from the rebound in China, where the market is ahead of the world in emerging from the COVID-19 induced lockdown.
China on its own showed a sales increase of 18.1 percent in the nine months while the broader Asia-Pacific was down just 1.9 percent.
L'Oreal made no forecast for the full year but said it expected a positive second half, with sales growing on a like-for-like basis, helped by soaring online demand – up more than 61 percent for the nine months and now accounts for nearly 24 percent of its business.
2026-08-22
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
China NMPA Issues Priority Review Pathway for Four Categories of Chemical Active Pharmaceutical Ingredients, Effective August 1, 2026
-
Pakistan Launches Successive Anti-dumping Investigations against Chinese Products, Involving Soda Ash, Ibuprofen and Other Raw Materials
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
WACKER’s 2025 Loss Reaches €805 Million as the PACE Cost-Cutting Plan Becomes the Key Variable for 2026
-
2026 Q1 Chemical Giant Earnings: Supply Contraction, Flat Demand, Full-Scale "Defense Priority"
-
FDA Color Policy Uncertainty Opens a New Chapter for Food Ingredient Reform
-
A Fake Email Drains RMB 12 Million: Asia’s Waterproof Giant’s Overseas ‘Payment Heist’ Exposes the Fatal Blind Spot of Chinese Corporate Globalization
-
关于将4-amino-1-boc-piperidine、tert-buty 4-aminopiperidine-1-carboxylate产品列入《ECHEMI平台禁限售商品目录》的公告 Announcement on Including 4-amino-1-boc-piperidine and tert-buty 4-aminopiperidine-1-carboxylate in the Announcement on the List of Prohibited Sales of Prohibited and Controlled Items on ECHEMI
-
EU Chemicals Regulatory Update: Practical Compliance Actions Following ECHA January 2026 Developments
-
Pesticide Market in Limbo: Prices Plunge Amid Weak Demand and Overcapacity—Only a Few Hold Firm
Recommend Reading
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
Vera’s New Kidney Drug Wins FDA Approval, Carrying a $425,000 Annual Price
-
South Korea Expands Mandatory GMO Labeling to Highly Processed Foods
-
Bayer and Syngenta Score Consecutive Regulatory and Legal Wins in the U.S.
-
China Releases 15th Five-Year Carbon-Peaking Action Plan, Pushing Coal Chemicals into a Mandatory Low-Carbon Upgrade Cycle
-
Chemical Properties and Applications of Cyclopropen
-
July Palm Oil Market Oscillates and Rises in China
-
Premium Global Chemical Sourcing Requests (6-10 Dec 2025)
-
Acetic Acid Prices Continue to Rise in Early December
-
Methylene Chloride Price Increase Slows, Expected to Stabilize with Slight Strength in the Short Term in China